154 related articles for article (PubMed ID: 38408692)
1. Indigenous wisdom of a Kwatha to treat NASH: An insight into the mechanism.
Yellurkar ML; Prasanna VS; Das P; Sarkar S; Matta R; Dhaked DK; Peraman R; Taraphdar AK; Nanjappan SK; Velayutham R; Arumugam S
J Ethnopharmacol; 2024 May; 326():117935. PubMed ID: 38408692
[TBL] [Abstract][Full Text] [Related]
2. Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation.
Zhang X; Gao R; Zhou Z; Sun J; Tang X; Li J; Zhou X; Shen T
J Ethnopharmacol; 2022 Oct; 296():115405. PubMed ID: 35644437
[TBL] [Abstract][Full Text] [Related]
3. Integrating transcriptomics and network pharmacology to reveal the mechanisms of total Rhizoma Coptidis alkaloids against nonalcoholic steatohepatitis.
Li J; Ma Z; Yang Z; Yang M; Li C; Li M; Li X; Chen X; Ma H; Chen W; Ye X; Li X
J Ethnopharmacol; 2024 Mar; 322():117600. PubMed ID: 38103844
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
5. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
6. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
8. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
10. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
[TBL] [Abstract][Full Text] [Related]
11. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
12. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
[No Abstract] [Full Text] [Related]
13. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
14. Integrating metabolomics and network pharmacology to reveal the mechanisms of Delphinium brunonianum extract against nonalcoholic steatohepatitis.
Zhang K; Yuan Y; Dawa Z; Liu F; Yao Y; Wang M; Zhu C; Lin C
J Ethnopharmacol; 2022 Jul; 293():115268. PubMed ID: 35398502
[TBL] [Abstract][Full Text] [Related]
15. Immune-metabolic interactions in homeostasis and the progression to NASH.
Hoogerland JA; Staels B; Dombrowicz D
Trends Endocrinol Metab; 2022 Oct; 33(10):690-709. PubMed ID: 35961913
[TBL] [Abstract][Full Text] [Related]
16. Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis: A Study of 2 Cohorts With Molecular Insights.
Qin J; Higashi T; Nakagawa S; Fujiwara N; Yamashita YI; Beppu T; Baba H; Kobayashi M; Kumada H; Gunasekaran G; Schiano TD; Thung SN; Fiel MI; Hoshida Y; Ward SC
Am J Surg Pathol; 2020 Oct; 44(10):1406-1412. PubMed ID: 32618599
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
18. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.
Takakura K; Oikawa T; Tomita Y; Mizuno Y; Nakano M; Saeki C; Torisu Y; Saruta M
World J Gastroenterol; 2018 May; 24(18):1989-1994. PubMed ID: 29760542
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
[TBL] [Abstract][Full Text] [Related]
20. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
